Apellis Pharmaceuticals Inc

NASDAQ:APLS   11:13:31 AM EDT
38.11
+0.89 (+2.39%)
Products, Regulatory

Apellis and Sobi Announce EU Approval of Aspaveli for Treatment of PNH

Published: 12/15/2021 13:15 GMT
Apellis Pharmaceuticals Inc (APLS) - Apellis and Sobi Announce Eu Approval of Aspaveli® (pegcetacoplan) for Treatment of Pnh.
Apellis Pharmaceuticals Inc - Approval Based on Results From Head-to-head Pegasus Phase 3 Study.
Apellis Pharmaceuticals Inc - Aspaveli Will Have Market Exclusivity for Paroxysmal Nocturnal Hemoglobinuria (pnh) Based on Orphan Drug Designation.